Research ExplorerPublicationsConsiderations in the development of circulating tumor cell ...

Considerations in the development of circulating tumor cell technology for clinical use.

Standard

Considerations in the development of circulating tumor cell technology for clinical use. / Parkinson, David R; Dracopoli, Nicholas; Petty, Brenda Gumbs; Compton, Carolyn; Cristofanilli, Massimo; Deisseroth, Albert; Hayes, Daniel F; Kapke, Gordon; Kumar, Prasanna; Lee, Jerry Sh; Liu, Minetta C; McCormack, Robert; Mikulski, Stanislaw; Nagahara, Larry; Pantel, Klaus; Pearson-White, Sonia; Punnoose, Elizabeth A; Roadcap, Lori T; Schade, Andrew E; Scher, Howard I; Sigman, Caroline C; Kelloff, Gary J.

In: J TRANSL MED, Vol. 10, 2012, p. 138.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Parkinson, DR, Dracopoli, N, Petty, BG, Compton, C, Cristofanilli, M, Deisseroth, A, Hayes, DF, Kapke, G, Kumar, P, Lee, JS, Liu, MC, McCormack, R, Mikulski, S, Nagahara, L, Pantel, K, Pearson-White, S, Punnoose, EA, Roadcap, LT, Schade, AE, Scher, HI, Sigman, CC & Kelloff, GJ 2012, 'Considerations in the development of circulating tumor cell technology for clinical use.', J TRANSL MED, vol. 10, pp. 138. https://doi.org/10.1186/1479-5876-10-138

APA

Parkinson, D. R., Dracopoli, N., Petty, B. G., Compton, C., Cristofanilli, M., Deisseroth, A., Hayes, D. F., Kapke, G., Kumar, P., Lee, J. S., Liu, M. C., McCormack, R., Mikulski, S., Nagahara, L., Pantel, K., Pearson-White, S., Punnoose, E. A., Roadcap, L. T., Schade, A. E., ... Kelloff, G. J. (2012). Considerations in the development of circulating tumor cell technology for clinical use. J TRANSL MED, 10, 138. https://doi.org/10.1186/1479-5876-10-138

Vancouver

Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A et al. Considerations in the development of circulating tumor cell technology for clinical use. J TRANSL MED. 2012;10:138. https://doi.org/10.1186/1479-5876-10-138

Bibtex

@article{bbc72b47e1ce454796d99c65b6922652,
title = "Considerations in the development of circulating tumor cell technology for clinical use.",
abstract = "This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development-analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug Administration (FDA) and the US National Cancer Institute (NCI).",
keywords = "Humans, Tumor Markers, Biological, *Neoplastic Cells, Circulating, Humans, Tumor Markers, Biological, *Neoplastic Cells, Circulating",
author = "Parkinson, {David R} and Nicholas Dracopoli and Petty, {Brenda Gumbs} and Carolyn Compton and Massimo Cristofanilli and Albert Deisseroth and Hayes, {Daniel F} and Gordon Kapke and Prasanna Kumar and Lee, {Jerry Sh} and Liu, {Minetta C} and Robert McCormack and Stanislaw Mikulski and Larry Nagahara and Klaus Pantel and Sonia Pearson-White and Punnoose, {Elizabeth A} and Roadcap, {Lori T} and Schade, {Andrew E} and Scher, {Howard I} and Sigman, {Caroline C} and Kelloff, {Gary J}",
year = "2012",
doi = "10.1186/1479-5876-10-138",
language = "English",
volume = "10",
pages = "138",
journal = "J TRANSL MED",
issn = "1479-5876",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Considerations in the development of circulating tumor cell technology for clinical use.

AU - Parkinson, David R

AU - Dracopoli, Nicholas

AU - Petty, Brenda Gumbs

AU - Compton, Carolyn

AU - Cristofanilli, Massimo

AU - Deisseroth, Albert

AU - Hayes, Daniel F

AU - Kapke, Gordon

AU - Kumar, Prasanna

AU - Lee, Jerry Sh

AU - Liu, Minetta C

AU - McCormack, Robert

AU - Mikulski, Stanislaw

AU - Nagahara, Larry

AU - Pantel, Klaus

AU - Pearson-White, Sonia

AU - Punnoose, Elizabeth A

AU - Roadcap, Lori T

AU - Schade, Andrew E

AU - Scher, Howard I

AU - Sigman, Caroline C

AU - Kelloff, Gary J

PY - 2012

Y1 - 2012

N2 - This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development-analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug Administration (FDA) and the US National Cancer Institute (NCI).

AB - This manuscript summarizes current thinking on the value and promise of evolving circulating tumor cell (CTC) technologies for cancer patient diagnosis, prognosis, and response to therapy, as well as accelerating oncologic drug development. Moving forward requires the application of the classic steps in biomarker development-analytical and clinical validation and clinical qualification for specific contexts of use. To that end, this review describes methods for interactive comparisons of proprietary new technologies, clinical trial designs, a clinical validation qualification strategy, and an approach for effectively carrying out this work through a public-private partnership that includes test developers, drug developers, clinical trialists, the US Food & Drug Administration (FDA) and the US National Cancer Institute (NCI).

KW - Humans

KW - Tumor Markers, Biological

KW - Neoplastic Cells, Circulating

KW - Humans

KW - Tumor Markers, Biological

KW - Neoplastic Cells, Circulating

U2 - 10.1186/1479-5876-10-138

DO - 10.1186/1479-5876-10-138

M3 - SCORING: Journal article

VL - 10

SP - 138

JO - J TRANSL MED

JF - J TRANSL MED

SN - 1479-5876

ER -